Zocor

Zocor is a brand name for the medication simvastatin. It belongs to a class of drugs called statins and is used to lower cholesterol levels in the blood. Here is some information about Zocor:

Treatment of High Cholesterol

Zocor (simvastatin) is primarily prescribed for the treatment of high cholesterol levels, specifically elevated levels of low-density lipoprotein (LDL) cholesterol, often referred to as “bad” cholesterol. It works by inhibiting an enzyme involved in the production of cholesterol in the liver, thereby reducing LDL cholesterol levels and promoting an increase in high-density lipoprotein (HDL) cholesterol, often referred to as “good” cholesterol.

Dosage and Usage

Zocor is available in tablet form and comes in different strengths. The appropriate dosage will depend on factors such as the individual’s cholesterol levels, overall health, and response to the medication. It is typically taken orally, once daily, with or without food. The specific dosage and duration of treatment will be determined by a healthcare professional.

It is important to take Zocor as prescribed and adhere to the recommended lifestyle changes, such as a healthy diet and regular exercise, to achieve optimal cholesterol-lowering effects.

Precautions and Potential Side Effects

Zocor is generally well-tolerated, but like any medication, it can have potential side effects. Common side effects may include headache, muscle pain or weakness, digestive issues, and changes in liver function tests. Rarely, more serious side effects such as liver problems or muscle breakdown (rhabdomyolysis) may occur. If any severe or persistent side effects occur, it is important to seek immediate medical attention.

Zocor may interact with certain medications, so it is important to inform your healthcare professional about all the medications you are currently taking.

Monitoring and Consultation with Healthcare Professional

During treatment with Zocor, regular monitoring of cholesterol levels and liver function tests may be recommended to assess the medication’s effectiveness and safety. It is important to attend follow-up appointments and report any concerns or changes in health to a healthcare professional.

Zocor is a prescription medication, and its use should be supervised by a healthcare professional. It is important to consult with a doctor or cardiologist to discuss your specific condition, determine the appropriate dosage, and address any questions or concerns regarding Zocor.

WARNING: Please consult with a healthcare professional or doctor for personalized advice and guidance regarding the use of Zocor or any other medication for the treatment of high cholesterol. They will be able to provide specific instructions based on your medical history and individual needs.

References

1. ^ “Active substance: simvastatin” (PDF). List of nationally authorised medicinal products. European Medicines Agency. 26 November 2020.
2. ^ Jump up to:^{a b c d e f g h i j k l m} “Simvastatin”. The American Society of Health-System Pharmacists. Archived from the original on 10 January 2015. Retrieved 8 January 2015.
3. ^ “Prescribing medicines in pregnancy database”. Australian Government. 3 March 2014. Archived from the original on 8 April 2014. Retrieved 22 April 2014.
4. ^ Jump up to:^a b Cechinel-Filho V (2012). Plant bioactives and drug discovery : principles, practice, and perspectives. Hoboken, N.J.: John Wiley & Sons. p. 104. ISBN 9780470582268. Archived from the original on 5 March 2016.
5. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 472. ISBN 9783527607495.
6. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
7. ^ “The Top 300 of 2020”. ClinCalc. Retrieved 7 October 2022.
8. ^ “Simvastatin – Drug Usage Statistics”. ClinCalc. Retrieved 7 October 2022.
9. ^ Pedersen TR, Tobert JA (December 2004). “Simvastatin: a review”. Expert Opinion on Pharmacotherapy. 5 (12): 2583–96. doi:10.1517/14656566.5.12.2583. PMID 15571475. S2CID 36911054.
10. ^ Jump up to:^a b “Zocor Full Prescribing Information” (PDF). U.S. Food and Drug Administration (FDA). Archived (PDF) from the original on 8 December 2015.
11. ^ Roizenblatt M, Naranjit N, Maia M, Gehlbach PL (November 2018). “The Question of a Role for Statins in Age-Related Macular Degeneration”. International Journal of Molecular Sciences. 19 (11): 3688. doi:10.3390/ijms19113688. PMC 6274767. PMID 30469381.
12. ^ Al-Holou SN, Tucker WR, Agrón E, Clemons TE, Cukras C, Ferris FL, Chew EY (December 2015). “The Association of Statin Use with Age-Related Macular Degeneration Progression: The Age-Related Eye Disease Study 2 Report Number 9”. Ophthalmology. 122 (12): 2490–6. doi:10.1016/j.ophtha.2015.08.028. PMC 4658271. PMID 26435335.
13. ^ Barbosa DT, Mendes TS, Cíntron-Colon HR, Wang SY, Bhisitkul RB, Singh K, Lin SC (April 2014). “Age-related macular degeneration and protective effect of HMG Co-A reductase inhibitors (statins): results from the National Health and Nutrition Examination Survey 2005-2008”. Eye. 28 (4): 472–80. doi:10.1038/eye.2014.8. PMC 3983650. PMID 24503725.
14. ^ Jump up to:^a b “Zocor”. RxList. 14 November 2012. Archived from the original on 4 November 2012. Retrieved 1 December 2012.
15. ^ “Simvastatin”. LactMed. U.S. National Library of Medicine. Retrieved 1 December 2012.
16. ^ Jump up to:^{a b c d e} “FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury”. U.S. Food and Drug Administration (FDA). 8 June 2011. Archived from the original on 11 June 2011.
17. ^ “Simvastatin: updated advice on drug interactions – updated contraindications”. Drug Safety Update. Government of the United Kingdom. 6 (1): S1. August 2012. Archived from the original on 27 January 2016. Retrieved 3 November 2015.
18. ^ “FDA Drug Safety Communication: Revised dose limitation for Zocor (simvastatin) when taken with amiodarone”. U.S. Food and Drug Administration (FDA). 15 December 2011. Archived from the original on 26 November 2012. Retrieved 12 October 2019.
19. ^ Baselt R (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, CA: Biomedical Publications. pp. 1431–3.
20. ^ rs4149056 Archived 11 January 2009 at the Wayback Machine
21. ^ Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. (August 2008). “SLCO1B1 variants and statin-induced myopathy–a genomewide study”. The New England Journal of Medicine. 359 (8): 789–99. doi:10.1056/NEJMoa0801936. PMID 18650507.
22. ^ Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, et al. (October 2014). “The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update”. Clinical Pharmacology and Therapeutics. 96 (4): 423–8. doi:10.1038/clpt.2014.125. PMC 4169720. PMID 24918167.
23. ^ Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, et al. (July 2012). “The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy”. Clinical Pharmacology and Therapeutics. 92 (1): 112–7. doi:10.1038/clpt.2012.57. PMC 3384438. PMID 22617227.
24. ^ “FDA Expands Advice on Statin Risks”. U.S. Food and Drug Administration (FDA). Archived from the original on 29 June 2012. Retrieved 12 July 2012.
25. ^ Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. (February 2010). “Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials”. Lancet. 375 (9716): 735–42. doi:10.1016/S0140-6736(09)61965-6. PMID 20167359. S2CID 11544414.
26. ^ “FDA Drug Safety Communication: Ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury”. U.S. Food and Drug Administration (FDA). 19 March 2010. Archived from the original on 20 March 2010. Retrieved 21 March 2010.
27. ^ Sternberg S (9 June 2011). “Simvastatin can damage muscles in high doses”. USA Today. Archived from the original on 11 June 2011. Retrieved 9 June 2011. The cholesterol-lowering drug simvastatin can cause severe muscle damage and should not be prescribed in high doses to patients who have taken it for less than a year or in any dose to people taking certain drugs, health officials said Tuesday. . . . Research has shown that the highest dose of simvastatin, 80 milligrams, causes muscle damage in 61 of every 1,000 patients, far higher than the eight-per-10,000 rate in patients taking a 40-milligram dose, Rosenblatt says.
28. ^ Lilja JJ, Kivistö KT, Neuvonen PJ (November 1998). “Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors”. Clinical Pharmacology and Therapeutics. 64 (5): 477–83. doi:10.1016/S0009-9236(98)90130-8. PMID 9834039. S2CID 37013910.
29. ^ Lilja JJ, Neuvonen M, Neuvonen PJ (July 2004). “Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin”. British Journal of Clinical Pharmacology. 58 (1): 56–60. doi:10.1111/j.1365-2125.2004.02095.x. PMC 1884539. PMID 15206993.
30. ^ “Cholesterol-lowering medicines, statins – Interactions”. NHS. 16 April 2012. Archived from the original on 28 September 2013. Retrieved 25 September 2013.
31. ^ Lilja JJ, Kivistö KT, Neuvonen PJ (October 2000). “Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin”. Clinical Pharmacology and Therapeutics. 68 (4): 384–90. doi:10.1067/mcp.2000.110216. PMID 11061578. S2CID 29029956.
32. ^ “Information on Simvastatin/Amiodarone”. U.S. Food and Drug Administration (FDA). 8 August 2008. Archived from the original on 7 June 2009. Retrieved 21 September 2008.
33. ^ Pedersen TR (2010). “Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering”. American Journal of Cardiovascular Drugs. 10 Suppl 1: 10–7. doi:10.2165/1158822-S0-000000000-00000. PMID 21391729. S2CID 23195784.
34. ^ Roy A, Jana M, Kundu M, Corbett GT, Rangaswamy SB, Mishra RK, et al. (August 2015). “HMG-CoA Reductase Inhibitors Bind to PPARα to Upregulate Neurotrophin Expression in the Brain and Improve Memory in Mice”. Cell Metabolism. 22 (2): 253–65. doi:10.1016/j.cmet.2015.05.022. PMC 4526399. PMID 26118928.
35. ^ Li JJ (2009). Triumph of the Heart: The Story of Statins. Oxford University Press. p. 59. ISBN 978-0198043515.
36. ^ Endo, Akira (2010). “A historical perspective on the discovery of statins”. Proceedings of the Japan Academy, Series B. 86 (5): 484–493. Bibcode:2010PJAB…86..484E. doi:10.2183/pjab.86.484. ISSN 0386-2208. PMC 3108295. PMID 20467214.
37. ^ Liao JK, Laufs U (2005). “Pleiotropic effects of statins”. Annual Review of Pharmacology and Toxicology. 45: 89–118. doi:10.1146/annurev.pharmtox.45.120403.095748. PMC 2694580. PMID 15822172.
38. ^ Williams O, Jacks AM, Davis J, Martinez S (1998). “Case 10: Merck(A): Mevacor”. In Allan Afuah (ed.). Innovation Management – Strategies, Implementation, and Profits. Oxford University Press. ISBN 978-0-19-511346-4. Retrieved 19 July 2006.
39. ^ Tobert JA (July 2003). “Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors”. Nature Reviews. Drug Discovery. 2 (7): 517–26. doi:10.1038/nrd1112. PMID 12815379. S2CID 3344720.
40. ^ Scandinavian Simvastatin Survival Study Group (November 1994). “Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)”. Lancet. 344 (8934): 1383–9. doi:10.1016/S0140-6736(94)90566-5. PMID 7968073. S2CID 5965882.
41. ^ Jump up to:^a b Berenson A (23 June 2006). “Merck Loses Protection for Patent on Zocor”. The New York Times. Archived from the original on 14 January 2015. Retrieved 14 January 2015.
42. ^ “PPACA no cost-share preventive medications” (PDF). Cigna. Retrieved 30 March 2020.
43. ^ “Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Recommendation Statement”. American Family Physician. 95 (2). 15 January 2017. Retrieved 31 March 2020.
44. ^ “Recommendation: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication”. United States Preventive Services Taskforce. 15 November 2016. Retrieved 7 May 2022.
45. ^ “Merck gets Zocor patent extension”. The Pharma Letter. 3 November 2002. Retrieved 12 October 2019.